Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD. Barrington SF, et al. Among authors: trotman j. J Clin Oncol. 2015 Apr 1;33(10):1221-3. doi: 10.1200/JCO.2014.59.9373. Epub 2015 Feb 17. J Clin Oncol. 2015. PMID: 25691678 No abstract available.
Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.
Tam CS, Trotman J, Opat S, Stern JC, Allewelt H, By K, Novotny W, Huang J, Tedeschi A. Tam CS, et al. Among authors: trotman j. Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990. Blood Adv. 2023. PMID: 36753605 Free PMC article. No abstract available.
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
Hapgood G, Civallero M, Stepanishyna Y, Vose J, Cabrera ME, Advani RH, Pileri SA, Manni M, Horwitz SM, Foss FM, Hitz F, Radford J, Dlouhy I, Chiattone C, Kim WS, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M. Hapgood G, et al. Among authors: trotman j. Blood Adv. 2023 Sep 12;7(17):5047-5054. doi: 10.1182/bloodadvances.2023010037. Blood Adv. 2023. PMID: 37163360 Free PMC article.
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study.
Trotman J, Presgrave P, Carradice DP, Lenton DS, Gandhi MK, Cochrane T, Badoux X, Carlson J, Nkhoma G, Butcher B, Nikpour A, Fulham M, Johnston AM. Trotman J, et al. Hemasphere. 2023 Feb 21;7(3):e836. doi: 10.1097/HS9.0000000000000836. eCollection 2023 Mar. Hemasphere. 2023. PMID: 36844180 Free PMC article. No abstract available.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: trotman j. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, Ling S, Ward C, Augustson BM, Trotman J, Harrison SJ, Tam CS; Medical and Scientific Advisory Group, Myeloma Australia. Talaulikar D, et al. Among authors: trotman j. Intern Med J. 2023 Apr;53(4):599-609. doi: 10.1111/imj.15980. Epub 2023 Apr 5. Intern Med J. 2023. PMID: 36441109
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N. Perram J, et al. Among authors: trotman j. Intern Med J. 2023 Jan;53(1):119-125. doi: 10.1111/imj.15978. Intern Med J. 2023. PMID: 36371767 Free PMC article.
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G. Trotman J, et al. J Clin Oncol. 2011 Aug 10;29(23):3194-200. doi: 10.1200/JCO.2011.35.0736. Epub 2011 Jul 11. J Clin Oncol. 2011. PMID: 21747087
PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.
Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T, Vera P, Salles G, Trotman J. Tychyj-Pinel C, et al. Among authors: trotman j. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):408-15. doi: 10.1007/s00259-013-2441-8. Epub 2014 Jan 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 24435770
PURPOSE: We aimed to compare the standardized central review of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scans performed after induction therapy for follicular lymphoma (FL) in the PRIMA study (Salles et al., Lancet 377:42-51, 2011; Trotman et a …
PURPOSE: We aimed to compare the standardized central review of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scans p …
179 results